Compare MLEC & PRFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MLEC | PRFX |
|---|---|---|
| Founded | 2008 | 2007 |
| Country | Cayman Islands | Israel |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6M | 2.7M |
| IPO Year | N/A | 2020 |
| Metric | MLEC | PRFX |
|---|---|---|
| Price | $6.48 | $0.95 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 608.9K | ★ 3.6M |
| Earning Date | 02-03-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $20.42 | N/A |
| Revenue Next Year | $30.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 170.36 | N/A |
| 52 Week Low | $3.08 | $0.61 |
| 52 Week High | $120.00 | $6.65 |
| Indicator | MLEC | PRFX |
|---|---|---|
| Relative Strength Index (RSI) | 64.21 | 55.33 |
| Support Level | $4.18 | $0.85 |
| Resistance Level | $12.96 | $1.59 |
| Average True Range (ATR) | 1.54 | 0.12 |
| MACD | 0.26 | 0.03 |
| Stochastic Oscillator | 46.59 | 32.66 |
Moolec Science SA is a science-based ingredient company focused on producing real animal proteins in plants through Molecular Farming, a technology in the alternative protein landscape. Its purpose is to upgrade the taste, nutrition, and affordability of alternative protein products while building a more sustainable and equitable food system. The company has various products in its pipeline such as; TSP Valorasoy which is a soy protein product to produce vegetable proteins with texture and fibrousness similar to those of meat, Glaso, a safflower oil with high levels of gamma-linolenic acid, SPC2 which is a plant-based chymosin, YEEA1, an extract derived from a novel yeast biomass with specific properties, and others. The company's revenues arise from operations in Argentina.
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.